MacroGenics to Participate in Upcoming Investor Conferences
August 31, 2023 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Aug. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results
August 09, 2023 16:01 ET
|
MacroGenics, Inc.
Advancing enrollment of TAMARACK Phase 2 study in metastatic castration-resistant prostate cancer (mCRPC) under revised protocol Initiating lorigerlimab Phase 2 study in mCRPC patients Achieved $50...
MacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call
July 31, 2023 17:35 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, July 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
MacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial Results
May 09, 2023 16:01 ET
|
MacroGenics, Inc.
ZYNYZ™ is third product approved in U.S. that originated from MacroGenics' pipelineMultiple Phase 2 programs advancing in metastatic castration-resistant prostate cancer (mCRPC)Cash runway through...
MacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call
May 04, 2023 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, May 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics to Participate in Upcoming Investor Conferences
April 24, 2023 18:15 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, April 24, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)
March 22, 2023 13:22 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, March 22, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
MacroGenics Provides Corporate Update and 2022 Financial Results
March 15, 2023 16:01 ET
|
MacroGenics, Inc.
Cash runway extended through 2025 with $250 million in non-dilutive funding over past eight months TAMARACK study design modified with objective of accelerating data readoutEncouraging lorigerlimab...
MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million
March 08, 2023 17:36 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, March 08, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call
March 07, 2023 18:00 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, March 07, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...